TY - JOUR
T1 - Long-Term Outcomes for Patients With Atypical or Malignant Meningiomas Treated With or Without Radiation Therapy
T2 - A 25-Year Retrospective Analysis of a Single-Institution Experience
AU - Kent, Collin L.
AU - Mowery, Yvonne M.
AU - Babatunde, Olayode
AU - Wright, Ato O.
AU - Barak, Ian
AU - McSherry, Frances
AU - Herndon, James E.
AU - Friedman, Allan H.
AU - Zomorodi, Ali
AU - Peters, Katherine
AU - Desjardins, Annick
AU - Friedman, Henry
AU - Sperduto, William
AU - Kirkpatrick, John P.
N1 - Funding Information:
Disclosures: Dr Kirkpatrick reports relevant financial activities outside of the submitted work, including research funding from Varian Medical Systems and BioMimetix and ownership in ClearSight RT, LLC. Dr Desjardins reports grants from Triphase Accelerator, Orbus Therapeutics, Symphogen, Celgene/Bristol-Myers Squibb, as well as personal fees from Istari Oncology outside of the submitted work. In addition, Dr Desjardins holds the following patents: Method of Treating Solid Tumor with Oncolytic Poliovirus (US 15/428510; licensed to Istari Oncology), Method of Treating Solid Tumor with Oncolytic Poliovirus (CA 2,892,183; licensed to Istari Oncology), Method of Treating Solid Tumor with Oncolytic Poliovirus (EP 13856989.2; licensed to Istari Oncology), Method of Treating Solid Tumor with Oncolytic Poliovirus (HK 15112399.5; licensed to Istari Oncology), Oncolytic Poliovirus for Human tumors (US 16/505,771; issued), Neoadjuvant cancer treatment (US 17/044,645; pending), Neoadjuvant cancer treatment (AU 2019247039; pending), Neoadjuvant cancer treatment (JP 2020-554198; pending), Neoadjuvant cancer treatment (South Korea 10-2020.7031272; pending), Neoadjuvant cancer treatment (Canada; pending), Neoadjuvant cancer treatment (PCT/US2019/025402; pending), Neoadjuvant cancer treatment (US 62/823,277; pending), Oncolytic Poliovirus for Human Tumors (US 17/016,699; pending), Sequential Anti-cancer Treatment (US 16/086,735; issued), and Neoadjuvant cancer treatment (China; pending). Dr Desjardins also holds stock options in Istari Oncology (<1% of all total shares issued by Istari Oncology). All other authors have no disclosures to declare.
Funding Information:
Sources of support: This work had no specific funding. Disclosures: Dr Kirkpatrick reports relevant financial activities outside of the submitted work, including research funding from Varian Medical Systems and BioMimetix and ownership in ClearSight RT, LLC. Dr Desjardins reports grants from Triphase Accelerator, Orbus Therapeutics, Symphogen, Celgene/Bristol-Myers Squibb, as well as personal fees from Istari Oncology outside of the submitted work. In addition, Dr Desjardins holds the following patents: Method of Treating Solid Tumor with Oncolytic Poliovirus (US 15/428510; licensed to Istari Oncology), Method of Treating Solid Tumor with Oncolytic Poliovirus (CA 2,892,183; licensed to Istari Oncology), Method of Treating Solid Tumor with Oncolytic Poliovirus (EP 13856989.2; licensed to Istari Oncology), Method of Treating Solid Tumor with Oncolytic Poliovirus (HK 15112399.5; licensed to Istari Oncology), Oncolytic Poliovirus for Human tumors (US 16/505,771; issued), Neoadjuvant cancer treatment (US 17/044,645; pending), Neoadjuvant cancer treatment (AU 2019247039; pending), Neoadjuvant cancer treatment (JP 2020-554198; pending), Neoadjuvant cancer treatment (South Korea 10-2020.7031272; pending), Neoadjuvant cancer treatment (Canada; pending), Neoadjuvant cancer treatment (PCT/US2019/025402; pending), Neoadjuvant cancer treatment (US 62/823,277; pending), Oncolytic Poliovirus for Human Tumors (US 17/016,699; pending), Sequential Anti-cancer Treatment (US 16/086,735; issued), and Neoadjuvant cancer treatment (China; pending). Dr Desjardins also holds stock options in Istari Oncology (<1% of all total shares issued by Istari Oncology). All other authors have no disclosures to declare.
Publisher Copyright:
© 2022 The Authors
PY - 2022/5/1
Y1 - 2022/5/1
N2 - Purpose: Atypical (World Health Organization [WHO] grade 2) and malignant (WHO grade 3) meningiomas have high rates of local recurrence, and questions remain about the role of adjuvant radiation therapy (RT) for patients with WHO grade 2 disease. These patients frequently require salvage therapy, and optimal management is uncertain given limited prospective data. We report on the long-term outcomes for patients with atypical and malignant meningiomas treated with surgery and/or RT at our institution. Methods and Materials: Data were collected through a retrospective chart review for all patients with WHO grade 2 or 3 meningiomas treated with surgery and/or RT at our institution between January 1992 and March 2017. Progression-free survival (PFS) and overall survival (OS) were described using the KaplanMeier estimator. The outcomes in the subgroups were compared with a log-rank test. A Cox proportional hazards model was used for the univariable and multivariable analyses of predictors of PFS. Results: A total of 66 patients were included in this analysis. The median follow-up was 12.4 years overall and 8.6 years among surviving patients. Fifty-two patients (78.8%) had WHO grade 2 meningiomas, and 14 patients (21.2%) had WHO grade 3 disease. Thirty-six patients (54.5%) were treated with surgery alone, 28 patients (42.4%) with surgery and adjuvant RT, and 2 patients (3%) with RT alone. Median PFS and OS were 3.2 years and 8.8 years, respectively. PFS was significantly improved with adjuvant RT compared with surgery alone (hazard ratio, 0.36; 95% confidence interval, 0.18-0.70). Patients with Ki-67 index >10% showed a trend toward worse PFS compared with patients with Ki-67 ≤10% (hazard ratio, 0.51; 95% confidence interval, 0.25-1.04). No significant differences in PFS or OS were observed with respect to Simpson or WHO grade. Conclusions: For patients with atypical or malignant meningiomas, adjuvant RT was associated with significantly improved PFS, and Ki-67 index >10% was associated with a trend toward worse PFS. Given the long-term survival, high recurrence rates, and efficacy of salvage therapy, patients with atypical and malignant meningiomas should be monitored systematically long after initial treatment.
AB - Purpose: Atypical (World Health Organization [WHO] grade 2) and malignant (WHO grade 3) meningiomas have high rates of local recurrence, and questions remain about the role of adjuvant radiation therapy (RT) for patients with WHO grade 2 disease. These patients frequently require salvage therapy, and optimal management is uncertain given limited prospective data. We report on the long-term outcomes for patients with atypical and malignant meningiomas treated with surgery and/or RT at our institution. Methods and Materials: Data were collected through a retrospective chart review for all patients with WHO grade 2 or 3 meningiomas treated with surgery and/or RT at our institution between January 1992 and March 2017. Progression-free survival (PFS) and overall survival (OS) were described using the KaplanMeier estimator. The outcomes in the subgroups were compared with a log-rank test. A Cox proportional hazards model was used for the univariable and multivariable analyses of predictors of PFS. Results: A total of 66 patients were included in this analysis. The median follow-up was 12.4 years overall and 8.6 years among surviving patients. Fifty-two patients (78.8%) had WHO grade 2 meningiomas, and 14 patients (21.2%) had WHO grade 3 disease. Thirty-six patients (54.5%) were treated with surgery alone, 28 patients (42.4%) with surgery and adjuvant RT, and 2 patients (3%) with RT alone. Median PFS and OS were 3.2 years and 8.8 years, respectively. PFS was significantly improved with adjuvant RT compared with surgery alone (hazard ratio, 0.36; 95% confidence interval, 0.18-0.70). Patients with Ki-67 index >10% showed a trend toward worse PFS compared with patients with Ki-67 ≤10% (hazard ratio, 0.51; 95% confidence interval, 0.25-1.04). No significant differences in PFS or OS were observed with respect to Simpson or WHO grade. Conclusions: For patients with atypical or malignant meningiomas, adjuvant RT was associated with significantly improved PFS, and Ki-67 index >10% was associated with a trend toward worse PFS. Given the long-term survival, high recurrence rates, and efficacy of salvage therapy, patients with atypical and malignant meningiomas should be monitored systematically long after initial treatment.
UR - http://www.scopus.com/inward/record.url?scp=85124485423&partnerID=8YFLogxK
U2 - 10.1016/j.adro.2021.100878
DO - 10.1016/j.adro.2021.100878
M3 - Article
AN - SCOPUS:85124485423
SN - 2452-1094
VL - 7
JO - Advances in Radiation Oncology
JF - Advances in Radiation Oncology
IS - 3
M1 - 100878
ER -